LBIO (Longevity Biomedical) EBITDA Margin %: 0.00% (As of . 20)


What is Longevity Biomedical EBITDA Margin %?

Longevity Biomedical LBIO EBITDA Margin % is 0.00% as of . 20.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Longevity Biomedical's EBITDA for the six months ended in . 20 was $0.00 Mil. Longevity Biomedical's Revenue for the six months ended in . 20 was $0.00 Mil. Therefore, Longevity Biomedical's EBITDA margin for the quarter that ended in . 20 was 0.00%.

Longevity Biomedical  (NAS:LBIO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Longevity Biomedical EBITDA Margin % Related Terms

Longevity Biomedical EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Longevity Biomedical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical EBITDA Margin % Chart

Longevity Biomedical Annual Data
Trend
EBITDA Margin %

Longevity Biomedical Semi-Annual Data
EBITDA Margin %

LBIO vs : EBITDA Margin % Comparison

For the Biotechnology subindustry, Longevity Biomedical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longevity Biomedical EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's EBITDA Margin % falls into.


Longevity Biomedical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Longevity Biomedical's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

Longevity Biomedical's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Longevity Biomedical (LBIO) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Longevity Biomedical and its competitors.
Is Longevity Biomedical's EBITDA Margin % too high?
Longevity Biomedical's current EBITDA Margin % is 0.00%.
How does Longevity Biomedical's EBITDA Margin % compare to ?
Longevity Biomedical's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Longevity Biomedical and its competitors. Longevity Biomedical's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Biomedical stock overvalued right now?
Longevity Biomedical (LBIO) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Longevity Biomedical (LBIO), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Biomedical Business Description

Comparable Companies
Address 12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.